Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 24817381)

Published in Int J Cancer on May 30, 2014


Laia Alemany1, Maëlle Saunier, Isabel Alvarado-Cabrero, Beatriz Quirós, Jorge Salmeron, Hai-Rim Shin, Edyta C Pirog, Núria Guimerà, Gustavo Hernandez-Suarez, Ana Felix, Omar Clavero, Belen Lloveras, Elena Kasamatsu, Marc T Goodman, Brenda Y Hernandez, Jan Laco, Leopoldo Tinoco, Daan T Geraets, Charles F Lynch, Vaclav Mandys, Mario Poljak, Robert Jach, Josep Verge, Christine Clavel, Cathy Ndiaye, JoEllen Klaustermeier, Antonio Cubilla, Xavier Castellsagué, Ignacio G Bravo, Michael Pawlita, William G Quint, Nubia Muñoz, Francesc X Bosch, Silvia de Sanjosé, HPV VVAP Study Group

Author Affiliations

1: Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.

Articles citing this

US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst (2015) 2.18

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis (2016) 1.20

Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13

Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior. Cancer Epidemiol Biomarkers Prev (2015) 0.97

HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol (2015) 0.90

The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa. J Clin Med (2015) 0.85

Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. J Infect Dis (2015) 0.84

Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men. J Clin Microbiol (2014) 0.83

Anal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi'an, China. PLoS One (2015) 0.83

Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan. Cancers (Basel) (2016) 0.81

Human papillomavirus and gastrointestinal cancer: A review. World J Gastroenterol (2016) 0.80

Diversity of human papillomavirus in the anal canal of men: the HIM Study. Clin Microbiol Infect (2015) 0.80

The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis. Virchows Arch (2015) 0.79

Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine (2015) 0.78

Prophylactic HPV vaccination and anal cancer. Hum Vaccin Immunother (2016) 0.78

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Vaccine (2015) 0.77

Prevalence of Anal HPV Infection Among HIV-Positive Men Who Have Sex With Men in India. J Acquir Immune Defic Syndr (2016) 0.77

Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci (2017) 0.76

Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. BMJ Open (2015) 0.76

Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis (2016) 0.75

Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with men. PLoS One (2015) 0.75

A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol (2016) 0.75

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. Oncologist (2017) 0.75

Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer (2017) 0.75

Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies. Front Public Health (2015) 0.75

Burden of Cancers Attributable to Infectious Agents in Nigeria: 2012-2014. Front Oncol (2016) 0.75

The burden of HPV associated cancers in two regions in Nigeria 2012-2014. Cancer Epidemiol (2016) 0.75

Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol Clin Res (2016) 0.75

Human papillomavirus (HPV) insertional mutation as a dynamic & specific tumour biomarker in HPV-associated carcinoma. Indian J Med Res (2015) 0.75

HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus. Cancer Med (2016) 0.75

HPV disease transmission protection and control. Microb Cell (2016) 0.75

High-risk human papillomavirus cervical infections among healthy women in Guadeloupe. Int J Infect Dis (2015) 0.75

Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb) (2017) 0.75

Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget (2017) 0.75

Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology (2017) 0.75

Articles cited by this

Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol (2003) 16.23

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol (1999) 6.45

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43

Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol (1998) 5.29

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer (2009) 4.28

Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer (2004) 4.04

Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer (2001) 3.61

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35

A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91

Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50

Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS (2009) 1.73

A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64

Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis (2005) 1.58

Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer (2011) 1.46

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42

Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer (2010) 1.38

The epidemiology of anal cancer. Sex Health (2012) 1.30

Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23

The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol (2013) 1.21

Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer (2012) 1.10

Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer (2013) 1.05

Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis (2013) 1.02

Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer (2013) 1.00

The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med (2013) 0.97

Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol (2012) 0.97

Human papillomavirus type 16 DNA in anal cancers from six different countries. Gut (1991) 0.96

Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol (2012) 0.90

High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr (2012) 0.83

One lesion, one virus: individual components of high-grade anal intraepithelial neoplasia in HIV-positive men contain a single HPV type. J Infect Dis (2014) 0.81

Articles by these authors

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67

International network of cancer genome projects. Nature (2010) 20.35

Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18

Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10

Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86

Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28

Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87

Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol (2002) 5.81

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet (2009) 5.32

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09

Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat (2009) 5.01

Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77

Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70

Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42

A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38

Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr (2003) 4.35

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31

A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29

Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol (2010) 4.26

Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14

Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98

The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86

Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci (2010) 3.79

Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ (2010) 3.41

Nitrate in public water supplies and the risk of colon and rectum cancers. Epidemiology (2003) 3.39

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35

Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15

Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09

Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07

Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med (2012) 3.06

A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03

Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa. Epidemiology (2002) 3.00

Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87

Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr (2003) 2.87

Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med (2005) 2.82

A combined analysis of North American case-control studies of residential radon and lung cancer. J Toxicol Environ Health A (2006) 2.78

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75

Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70

Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63

Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci (2009) 2.61

Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60

Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology (2005) 2.56

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics (2006) 2.55

Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet (2008) 2.53

The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52

Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol (2002) 2.51

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49